Abemaciclib Plus Fulvestrant in Advanced Breast Cancer After Progression on CDK4/6 Inhibition: Results From the Phase III postMONARCH Trial
Yet another combination to consider after CDK4/6i + ET in HR+ MBC!
Utility of the 70-Gene MammaPrint Assay for Prediction of Benefit From Extended Letrozole Therapy in the NRG Oncology/NSABP B-42 Trial
Author(s): Priya Rastogi, MD1,2; Hanna Bandos, PhD3,4; Peter C. Lucas, MD, PhD1; Laura J. van ‘t Veer, PhD5; Jia-Perng J. Wei, MD, PhD5; Charles E. Geyer, Jr, MD1; Louis Fehrenbacher, MD6; Stephen K.L. Chia, MD7; Adam M. Brufsky, MD, PhD1,2; Janice M. Walshe, MD8; Gamini S. Soori, MD9; Shaker R. Dakhil, MD10; Soonmyung Paik, MD11,12; Sandra M. Swain, MD13; Andrea R. Menicucci, PhD5; M. William Audeh, MD5; Norman Wolmark, MD1; Eleftherios P. Mamounas, MD14
Source: https://doi.org/10.1200/JCO.23.01995
Dr. Maen Hussein's Thoughts
MammaPrint did not predict distant recurrence, but it did predict patients who may benefit from extended hormonal therapy. We do have breast index, so now we have options. Breast index can predict the possibility of recurrence though by helping to determine the level of risk.
PURPOSE
MammaPrint (MP) determines distant metastatic risk and may improve patient selection for extended endocrine therapy (EET). This study examined MP in predicting extended letrozole therapy (ELT) benefit in patients with early-stage breast cancer (BC) from the NSABP B-42 trial.
PATIENTS AND METHODS
MP was tested in 1,866 patients randomly assigned to receive ELT or placebo. The primary end point was distant recurrence (DR). Secondary end points were disease-free survival (DFS) and BC-free interval (BCFI). Tumors were classified as MP high risk (MP-HR) or low risk (MP-LR). MP-LR tumors were further classified as ultralow risk (MP-UL) or low non-ultralow risk (MP-LNUL).
RESULTS
There was no statistically significant difference in ELT benefit on DR between MP-HR and MP-LR (interaction P = .38). MP-LR tumors (n = 1,160) exhibited a statistically significant 10-year benefit of 3.7% for DR (hazard ratio [HR], 0.43 [95% CI, 0.25 to 0.74]; P = .002), whereas MP-HR tumors (n = 706) exhibited a nonsignificant 2.4% benefit (HR, 0.65 [95% CI, 0.34 to 1.24]; P = .19). The 10-year ELT benefit was significant for DFS (7.8%) and BCFI (7.0%) for MP-LR tumors, whereas MP-HR tumors did not significantly benefit (interaction DFS: P = .015, BCFI: P = .006). In exploratory analysis, the 10-year ELT benefit was significant and more pronounced in MP-LNUL (n = 908) tumors: 4.0% for DR, 9.5% for DFS, and 7.9% for BCFI; the benefit in MP-UL (n = 252) tumors was not significant: 3% for DR, 1.8% for DFS, and 4.1% for BCFI.
CONCLUSION
The primary hypothesis of predictive ability of MP on DR was not confirmed. However, the secondary outcomes demonstrated MP was predictive of ELT response and identified a subset of patients with early-stage hormone receptor–positive BC (MP-LR) with improved outcomes from ELT. These data could have important clinical implications in patient selection beyond clinical risk assessment for EET.
Author Affiliations
1UPMC Hillman Cancer Center, University of Pittsburgh School of Medicine, Pittsburgh, PA; 2Magee-Women’s Hospital, Pittsburgh, PA; 3NRG Oncology SDMC, Pittsburgh, PA; 4University of Pittsburgh, School of Public Health, Pittsburgh, PA; 5Agendia, Inc, Irvine, CA; 6Kaiser Permanente Oncology Clinical Trials Northern CA, Novato, CA; 7British Columbia Cancer Agency, Vancouver, BC, Canada; 8Cancer Trials Ireland, and St Vincent’s University Hospital, Dublin, Ireland; 9Florida Cancer Specialists, Fort Myers, FL; 10Wichita NCORP, Via Christi Regional Medical Center, and Cancer Center of Kansas, Wichita, KS; 11Theragenbio, Inc, Pankyo, Republic of Korea; 12Severance Biomedical Science Institute, Yonsei University College of Medicine, Seoul, Republic of Korea; 13Georgetown Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC; 14Advent Health Cancer Center, Orlando, FLRelated Articles
Axillary Surgery in Breast Cancer — Primary Results of the INSEMA Trial
The INSEMA trial showed that for early stage, T1-T2 clinically node negative breast cancer, sentinel lymph node biopsies should not be mandatory, and best clinical judgement can be used.
Imlunestrant with or without Abemaciclib in Advanced Breast Cancer
Imlunestrant (novel oral SERD) was active in patients with an ESR1 mutations, but otherwise did not offer a benefit in this population of women with ER+ HER2-neg MBC. Overall survival (OS) data is pending with further follow up.
Camrelizumab vs Placebo in Combination With Chemotherapy as Neoadjuvant Treatment in Patients With Early or Locally Advanced Triple-Negative Breast Cancer
Another trial with neoadjuvant immunotherapy showing improved results over chemotherapy alone. (12% higher PCR 48% vs 36%).
Datopotamab Deruxtecan Versus Chemotherapy in Previously Treated Inoperable/Metastatic Hormone Receptor–Positive Human Epidermal Growth Factor Receptor 2–Negative Breast Cancer: Primary Results From TROPION-Breast01
Dato-DXd is now approved in HR+, HER2-neg, metastatic breast cancer after prior therapy with endocrine-based therapy and chemotherapy. There was an impressive reduction in the risk of death or progression with an HR of 0.63. Watch out for ocular and pulmonary toxicity. HER2-ultra low testing will be burdensome but must be done for drug approval.
